8 May 2012
A revolutionary cancer-targeting technology developed by researchers at Immunocore Limited has been described for the first time in the prestigious medical journal, Nature Medicine. The new reagents known as ImmTACs (Immune Mobilising mTCR against Cancer) mobilise T cells to kill cancer cells and overcome immune tolerance to cancer.
Please click on the link below to download the full Press Release:
Revolutionary new cancer targeting technology described in Nature Medicine
